Recombinant Bacillus subtilis Uncharacterized protein ydgA (ydgA)

Shipped with Ice Packs
In Stock

Description

Bacillus subtilis as a Recombinant Host

Advantages:

  • GRAS Status: FDA-recognized as a safe organism, enabling applications in food and pharmaceuticals .

  • Efficient Secretion: Utilizes Sec and Tat pathways for extracellular protein export, with secretion yields exceeding 2 mg/L in some systems .

  • Genetic Flexibility: Natural competence for DNA uptake and CRISPR-based genome editing tools facilitate strain optimization .

Challenges:

  • Proteolytic Degradation: Proteases like HtrA may degrade heterologous proteins. Engineering proteolytically inactive variants (e.g., HtrA mutants) can mitigate this .

Functional Characterization of Analogous Proteins

While ydgA remains uncharacterized, studies of similar B. subtilis proteins provide context:

  • YdaF (Ribosomal N-Acetyltransferase): Structurally resembles other NATs, with a hexameric structure and conserved AcCoA-binding motifs .

  • AmyQ (α-Amylase): Achieves high yields (e.g., 2.5 g/L) via engineered secretion systems and stress response modulation .

Research Findings and Data

Table 1: Comparison of Recombinant Protein Production in B. subtilis vs. E. coli

FeatureB. subtilisE. coli
Endotoxin PresenceAbsent (GRAS status)Present
Secretion Efficiency2-5 g/L (optimized systems)1-3 g/L
Fermentation Time48 hours72-96 hours
Host Strain CostModerate ($10,000–$20,000/year)High ($50,000–$100,000/year)

Source: Adapted from BioProcess International .

Figure 1: Recombinant Protein Yields in B. subtilis

  • AmyQ: 2.5 g/L (shake flask) .

  • His-HRV3C: 8065 U/mg (cytoplasmic expression) .

Implications for ydgA Research

The lack of specific data on ydgA highlights gaps in understanding B. subtilis’ uncharacterized proteins. Future studies could:

  • Determine Function: Use bioinformatics (e.g., BLAST) to predict ydgA’s role (e.g., stress response, metabolism).

  • Optimize Expression: Leverage inducible promoters (e.g., Pgrac212) and secretion systems to enhance yields .

  • Assess Biotechnological Potential: Evaluate ydgA’s enzymatic or therapeutic properties via biochemical assays .

Product Specs

Form
Lyophilized powder. We will ship the available format, but please specify any format requirements when ordering, and we will accommodate your request.
Lead Time
Delivery times vary based on purchasing method and location. Consult your local distributor for specific delivery times. All proteins are shipped with standard blue ice packs. Request dry ice shipment in advance for an extra fee.
Notes
Avoid repeated freezing and thawing. Store working aliquots at 4°C for up to one week.
Reconstitution
Briefly centrifuge the vial before opening. Reconstitute the protein in sterile deionized water to 0.1-1.0 mg/mL. Add 5-50% glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final glycerol concentration is 50%.
Shelf Life
Shelf life depends on storage conditions, buffer components, storage temperature, and protein stability. Liquid form is generally stable for 6 months at -20°C/-80°C. Lyophilized form is generally stable for 12 months at -20°C/-80°C.
Storage Condition
Store at -20°C/-80°C upon receipt. Aliquot for multiple uses. Avoid repeated freeze-thaw cycles.
Tag Info
The tag type is determined during manufacturing. If you require a specific tag, please inform us, and we will prioritize its development.
Synonyms
ydgA; BSU05560Uncharacterized protein YdgA
Buffer Before Lyophilization
Tris/PBS-based buffer, 6% Trehalose.
Datasheet
Please contact us to get it.
Expression Region
1-80
Protein Length
full length protein
Purity
>85% (SDS-PAGE)
Species
Bacillus subtilis (strain 168)
Target Names
ydgA
Target Protein Sequence
MPYQINIANI KINGVTQNGN IDVGPTVHNS HTANSKYFGA NFSLGDLSPT SSLLNTGNID SDVSDQDQIG NPSAPISNQI
Uniprot No.

Q&A

Gene Function and Characterization

Q: What experimental approaches can be used to determine the functional role of ydgA in Bacillus subtilis?

A: To characterize ydgA, researchers should employ:

  • Knockout mutagenesis: Generate ydgA deletion mutants and assess phenotypic changes (e.g., metabolic profiles, stress responses) .

  • Proteomics: Use quantitative shotgun proteomics to identify proteins co-fractionating with ydgA, suggesting functional associations (e.g., membrane complexes, metabolic pathways) .

  • Enzymatic assays: Purify recombinant ydgA and test for catalytic activity (e.g., reductase, dehydrogenase) in vitro .

Q: How can conflicting data on ydgA’s role be resolved?

A: Address contradictions through:

  • Comparative genomics: Align ydgA sequences with homologs in other species (e.g., Bacillus cereus, Saccharomyces cerevisiae) to infer conserved domains .

  • Multi-omic integration: Combine transcriptomic, metabolomic, and proteomic data to contextualize ydgA expression patterns under varying conditions .

Expression and Purification

Q: What strategies optimize recombinant ydgA production in Bacillus subtilis?

A: Use:

  • Inducible promoters (e.g., Pgrac) for controlled expression .

  • Chaperone co-expression to improve solubility .

  • Triton X-100/EDTA treatments for membrane protein solubilization .

Q: What purification methods are suitable for ydgA?

A: For soluble vs. insoluble fractions:

FractionMethodRationale
Soluble cytoplasmicNi-NTA affinity chromatographyTags (e.g., His6) enable high-purity capture
Membrane-associatedSize exclusion chromatographySeparate by molecular weight (e.g., >280 kDa)

Experimental Design and Challenges

Q: How should experimental units be defined in ydgA studies?

A: Use the Experimental Design Assistant (EDA) to:

  • Randomize treatments (e.g., induction conditions)

  • Blind sample processing to reduce bias

  • Calculate sample sizes for statistical power .

Q: What challenges arise in validating ydgA’s role in Bacillus subtilis?

A: Address:

  • Low expression yields: Optimize codon usage or use alternative hosts (e.g., E. coli) .

  • Functional redundancy: Use double-knockout mutants to disentangle overlapping pathways .

  • Data reproducibility: Standardize growth conditions (e.g., media, temperature) and replicate experiments .

Data Analysis and Interpretation

Q: How to analyze proteomic data for ydgA interactions?

A: Implement:

  • Co-fractionation analysis: Identify proteins consistently co-eluting with ydgA during size exclusion chromatography .

  • Network modeling: Use STRING or Cytoscape to map predicted interactions based on homology .

Q: What statistical methods are appropriate for comparing ydgA expression across conditions?

A: Apply:

  • Two-way ANOVA for factorial designs (e.g., strain × treatment)

  • DESeq2 for RNA-seq data normalization and differential expression analysis .

Comparative Studies and Protein Interactions

Q: How to compare ydgA’s interactions with other Bacillus proteins?

A: Use:

  • Blue native PAGE: Resolve native complexes to estimate molecular weight .

  • Crosslinking mass spectrometry: Identify direct binding partners in vivo .

Q: What insights can be drawn from analogous studies (e.g., ydjL)?

A: The ydjL gene encodes acetoin reductase, critical for 2,3-butanediol biosynthesis . For ydgA:

  • Metabolic profiling: Measure metabolite levels (e.g., acetoin, butanediol) in ydgA mutants.

  • Enzyme activity assays: Test ydgA for reductase activity using NAD+/NADP+ cofactors .

Challenges and Limitations in Research

Q: Why might ydgA remain uncharacterized despite genomics efforts?

A: Contributing factors include:

  • Low expression levels: Below detection thresholds in standard proteomics workflows.

  • Functional redundancy: Multiple paralogs masking individual knockout effects.

  • Technical hurdles: Membrane localization complicating purification .

Q: How to address gaps in functional annotation?

A: Prioritize:

  • Bioinformatics: Predict domains (e.g., PFAM, InterPro) for biochemical clues.

  • Collaborative networks: Partner with structural biologists for X-ray crystallography .

Collaboration and Mentoring in Research

Q: What mentorship strategies enhance ydgA research productivity?

A: Effective advisors:

  • Co-develop mutual expectations: Align goals with trainees (e.g., publication targets, skill development) .

  • Advocate for resources: Secure funding for specialized equipment (e.g., mass spectrometers).

  • Foster interdisciplinary networks: Introduce trainees to bioinformaticians or microbiologists .

Q: How to design a robust research plan for ydgA studies?

A: Use the Individual Development Plan (IDP) to:

  • Timeline milestones (e.g., cloning, purification, assays)

  • Identify skill gaps (e.g., bioinformatics, mass spectrometry)

  • Schedule regular progress reviews .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.